Friday, May 6, 2016

Tuesday Features

Profound Medical readies pivotal clinical trial of TULSA-PRO

Profound Medical readies pivotal clinical trial of TULSA-PRO

Steve Plymale After receiving CE Mark approval last month of its minimally invasive transurethral ultrasound technology for the ablation of benign and malignant prostate tissue, known as TULSA-PRO, Profound Medical (TSX-V:PRN) plans to enroll 14 sites in the U.S., Canada and Europe in a pivotal trial for U.S. regulatory approval. “We have discussions... [Read more of this feature]


In conversation with Paul Gunn

In conversation with Paul Gunn

Paul Gunn As president and CEO of closely-held Soricimed Biopharma, Paul Gunn parlayed a 20-year career as a financial executive into funding the startup of Soricimed along with a tech transfer in 2005 facilitated by Mount Allison University in Sackville, New Brunswick, Canada. Admittedly, he was new to biotech and drug development in those days, but... [Read more of this feature]


Xagenic readies X1 molecular diagnostic beta trials

Xagenic readies X1 molecular diagnostic beta trials

Closely-held Xagenic plans to conduct beta studies this year, in advance of a major chlamydia and gonorrhea clinical trial, with its rapid X1 molecular diagnostic testing system in preparation for market launches in Europe and the U.S. “The Xagenic X1 platform is a revolutionary diagnostic sys­tem that allows the user to perform lab-quality molecular... [Read more of this feature]


More Posts From Tuesday Features

Briefs

TearLab Q1 revenue climbs 25%

TearLab Q1 revenue climbs 25%

First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 25% to $6.8-million from $5.4-million a year ago. A net total of 257 TearLab Osmolarity Systems were added in the first quarter of 2016, of which 167 were under the company’s new Flex program and 61 were purchased outside of the U.S. “While we had to make some difficult decisions... [Read more of this brief]


Titan Pharma’s Probuphine featured on CNBC

Titan Pharma’s Probuphine featured on CNBC

CNBC has highlighted Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant of buprenorphine in a feature about the treatment of opioid addiction and the crisis of fatal overdoses in the U.S. The feature discusses the potential benefits of an implant, compared with current sublingual versions of buprenorphine, and the relatively low... [Read more of this brief]


TearLab prices $17.3-million registered public offering

TearLab prices $17.3-million registered public offering

TearLab (NASDAQ:TEAR; TSX:TLB) has priced a public offering of common stock to raised gross proceeds of approximately $17.3-million to close on May 9. The offering was priced at 75 cents a share of common stock, or common stock equivalent, with each share of common stock coupled with a warrant to purchase one-half of one share of common stock. The warrants... [Read more of this brief]


Leerink downgrades Sarepta to under perform

Leerink downgrades Sarepta to under perform

Leerink has downgraded Sarepta Therapeutics (NASDAQ:SRPT) to “under perform” and slashed its price target to $5 from $13. The stock closed at $17.92 on Monday. Sarpeta has been a confounding stock for which to forecast each twist and turn, but now going into the PDUFA of May 26, 2016, we believe investors have the most information yet available... [Read more of this brief]


Zomedica Pharma listed on TSX Venture

Zomedica Pharma listed on TSX Venture

The shares of Zomedica Pharmaceuticals (TSX-V:ZOM), a veterinary pharmaceutical company, have been listed on TSX Venture Exchange under the symbol, ZOM. “With our shares trading on TSX-V, Zomedica has a more-efficient method for raising capital to bring our veterinarian-focused products to market while concurrently delivering liquidity for shareholders,”... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+